Press release
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022
- Approximately $71 Million of International Product Sales in 2022 - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, March 02, 2023 (GLOBE
About this update from Siga Technologies Inc.
[{"type":"text","content":"- Approximately $71 Million of International Product Sales in 2022 - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2022. “In 2022, SIGA had approximately $111 million in revenue including approximately $71 million of international sales. Importantly, we generated revenue from a more diversified customer base compared to previous years,” said Phil Gomez, CEO of SIGA. “The year included the first sale of the intravenous formulation of TPOXX® (“IV TPOXX”) to the U.S. Government, the first sales of oral TPOXX to the U.S. Department of Defense (“DoD”), and the sale of oral TPOXX (tecovirimat) to twelve new international customers. Our focus on customer diversification played a key role in helping us generate pre-tax operating income of approximately $43 million in 2022, a period during which the U.S. Government did not replace any quantities of TPOXX in the Strategic National Stockpile based on expirations.” Summary Financial Results($ in millions, except per share amounts) Three Months Ended December 31, 2022 in comparison to Three Months Ended December 31, 2021 Three Months Ended December 31,2022 Three Months EndedDecember 31, 2021Total RevenuesOperating (Loss) Income (1)(Loss) Income before Income Taxes (1)Net (Loss) Income Diluted (Loss) Income per Share$11.4($1.8)($1.2)($0.8) ($.01) per share $115.4$94.0$93.9$73.2 $0.98 per share Year Ended December 31, 2022 in comparison to Year Ended December 31, 2021 Year EndedDecember 31, 2022 Year EndedDecember 31, 2021Total RevenuesOperating Income (1)Income before Income Taxes (1)Net Income Diluted Income per Share$110.8$42.7$44.1$33.9$0.46 per share $133.7$89.1$89.3$69.5$0.91 per share (1) Operating Income (Loss) excludes, and Income (Loss) before Income Taxes includes, other income and adjustments to the fair value of the Company’s outstanding warrant. Both line items exclude the impact of income taxes. Key Business and Operational Activity for 2022: In 2022, SIGA received approximately $77 million of international orders for oral TPOXX (tecovirimat) from 13 customers, of which 12 were new customers in 2022. Approximately $71 million of these orders were delive...